{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=weekly+Epo&page=3", "query": { "intervention": "weekly Epo", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 77, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=weekly+Epo&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=weekly+Epo&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T08:38:54.129Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04410198", "title": "Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia Associated With End Stage Renal Disease (ESRD)" ], "interventions": [ { "name": "Roxadustat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyntra Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 203, "start_date": "2020-05-26", "completion_date": "2021-10-11", "has_results": true, "last_update_posted_date": "2022-09-13", "last_synced_at": "2026-10-04T08:38:54.129Z", "location_count": 9, "location_summary": "Englewood, Colorado • Caldwell, Idaho • Baton Rouge, Louisiana + 6 more", "locations": [ { "city": "Englewood", "state": "Colorado" }, { "city": "Caldwell", "state": "Idaho" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Kalamazoo", "state": "Michigan" }, { "city": "Tupelo", "state": "Mississippi" } ], "official_url": "https://clinicaltrials.gov/study/NCT04410198" }, { "nct_id": "NCT00520468", "title": "Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Erythropoietin", "type": "DRUG" }, { "name": "Cyclosporin A", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 15, "start_date": "2004-06", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2012-08-07", "last_synced_at": "2026-10-04T08:38:54.129Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00520468" }, { "nct_id": "NCT03277183", "title": "Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Anemia", "CKD", "Atherosclerosis", "Cardiovascular" ], "interventions": [ { "name": "Low dose erythropoietin", "type": "DRUG" }, { "name": "High dose erythropoietin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2017-11-02", "completion_date": "2019-06-03", "has_results": true, "last_update_posted_date": "2020-08-13", "last_synced_at": "2026-10-04T08:38:54.129Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03277183" }, { "nct_id": "NCT01414075", "title": "Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dialysis", "Anemia" ], "interventions": [ { "name": "Roxadustat", "type": "DRUG" }, { "name": "Oral Iron", "type": "DRUG" }, { "name": "IV Iron", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyntra Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 60, "start_date": "2011-07-21", "completion_date": "2013-01-10", "has_results": true, "last_update_posted_date": "2021-10-01", "last_synced_at": "2026-10-04T08:38:54.129Z", "location_count": 3, "location_summary": "Northridge, California • Yuba City, California • Detroit, Michigan", "locations": [ { "city": "Northridge", "state": "California" }, { "city": "Yuba City", "state": "California" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01414075" }, { "nct_id": "NCT00258440", "title": "Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anemia", "Fatigue", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "Weekly procrit dosing", "type": "DRUG" }, { "name": "Interval Dosing", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2003-05", "completion_date": "2008-09", "has_results": true, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-10-04T08:38:54.129Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00258440" }, { "nct_id": "NCT00597753", "title": "Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Renal Failure", "Chronic Kidney Disease", "Anemia" ], "interventions": [ { "name": "peginesatide", "type": "DRUG" }, { "name": "Epoetin Alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Affymax", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 803, "start_date": "2007-09", "completion_date": "2010-01", "has_results": true, "last_update_posted_date": "2013-02-12", "last_synced_at": "2026-10-04T08:38:54.129Z", "location_count": 89, "location_summary": "Paragould, Arkansas • Fairfield, California • Granada Hills, California + 76 more", "locations": [ { "city": "Paragould", "state": "Arkansas" }, { "city": "Fairfield", "state": "California" }, { "city": "Granada Hills", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00597753" }, { "nct_id": "NCT00077623", "title": "A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia" ], "interventions": [ { "name": "epoetin alfa or beta", "type": "DRUG" }, { "name": "methoxy polyethylene glycol-epoetin beta (Mircera)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 572, "start_date": "2004-03", "completion_date": "2005-09", "has_results": true, "last_update_posted_date": "2016-05-25", "last_synced_at": "2026-10-04T08:38:54.129Z", "location_count": 17, "location_summary": "Hot Springs, Arkansas • Los Angeles, California • Riverside, California + 14 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Jose", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00077623" }, { "nct_id": "NCT03169881", "title": "Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neurocognitive", "Neuroprotective", "Neonatal", "Neurodevelopmental Impairment" ], "interventions": [ { "name": "Darbepoetin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NICHD Neonatal Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Hour", "maximum_age": "24 Hours", "sex": "ALL", "summary": "1 Hour to 24 Hours" }, "enrollment_count": 650, "start_date": "2017-09-20", "completion_date": "2025-05-12", "has_results": true, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-04T08:38:54.129Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT03169881" }, { "nct_id": "NCT00058331", "title": "Epoetin Alfa in Treating Anemia in Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Precancerous Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "epoetin alfa", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 365, "start_date": "2003-06", "completion_date": "2006-05", "has_results": false, "last_update_posted_date": "2016-07-18", "last_synced_at": "2026-10-04T08:38:54.129Z", "location_count": 18, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 15 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00058331" }, { "nct_id": "NCT01467115", "title": "Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Radiotherapy", "type": "RADIATION" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Erythropoetin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG", "BIOLOGICAL" ], "sponsor": "Drexel University College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2010-03", "completion_date": "2014-10-07", "has_results": false, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-10-04T08:38:54.129Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01467115" } ] }